Filing Details

Accession Number:
0001415889-23-015458
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-11-22 19:00:20
Reporting Period:
2023-11-20
Accepted Time:
2023-11-22 19:00:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1750284 Olema Pharmaceuticals Inc. OLMA Pharmaceutical Preparations (2834) 300409740
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1831216 C. David Myles C/O Olema Pharmaceuticals, Inc.
780 Brannan St
San Francisco CA 94103
Ch. Discov. & Non-Clin Dev Off No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-11-20 26,250 $0.00 587,728 No 4 A Direct
Common Stock Disposition 2023-11-21 6,776 $14.87 580,952 No 4 S Direct
Common Stock Disposition 2023-11-21 200 $15.32 580,752 No 4 S Direct
Common Stock Disposition 2023-11-22 6,653 $13.89 574,099 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 12,831 Indirect See Footnote
Common Stock 154,846 Indirect See Footnote
Footnotes
  1. On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 75,000 shares, which are subject to vestingupon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified onNovember 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria.
  2. Includes 208 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2023.
  3. The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with thevesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent adiscretionary trade by the Reporting Person.
  4. The weighted average sale price for the transaction reported was $14.87, and the range of prices was between $14.26 and $15.25. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
  5. The weighted average sale price for the transaction reported was $15.32, and the range of prices was between $15.28 and $15.35. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
  6. The weighted average sale price for the transaction reported was $13.89, and the range of prices was between $13.62 and $14.15. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
  7. The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.
  8. The shares are held by Myles Properties Inc., of which the Reporting Person is President.